Stanford Medicine researchers report that blocking the aging-associated enzyme 15-hydroxyprostaglandin dehydrogenase (15-PGDH) with a small molecule inhibitor (PGDHi) regenerates joint cartilage and can halt osteoarthritis progression after joint injuries, signaling a potential shift in how we approach joint repair.

In studies led by Stanford, inhibiting 15-PGDH regrew lost knee cartilage in older mice and prevented arthritis after ACL-like injuries, suggesting the approach could reverse damage rather than merely treat symptoms.

Human cartilage samples treated in culture showed reduced breakdown activity and a shift toward cartilage-building gene expression within a week, with formation of new articular cartilage observed.

Researchers emphasize that the regenerative effect comes from reprogramming of native chondrocytes’ gene activity rather than activating stem cells, marking a novel route for tissue regeneration.

An oral form of the 15-PGDH inhibitor is already in trials for age-related muscle weakness, suggesting a faster path to broader applications, including cartilage repair, pending safety and activity data.

Unlike stem-cell–based therapies, this method reprograms existing cartilage cells (chondrocytes) to regenerate tissue, offering a distinct regenerative pathway.

Osteoarthritis affects about 20% of U.S. adults and costs roughly $65 billion annually in direct healthcare, underscoring the potential impact of a disease-modifying cartilage repair approach.

Clinical context: current OA therapies do not slow or reverse progression, which heightens the potential impact if 15-PGDH inhibition can alter the disease course.

In aged mice, PGDHi restored thinning articular cartilage to functional hyaline cartilage, with effects seen via both systemic and local knee injections.

Single-cell analyses show aging chondrocytes shift toward inflammatory and fibrocartilage gene expression, while 15-PGDH inhibition reverses these changes and increases cells associated with hyaline cartilage formation.

Tests on human knee tissue from surgeries showed new functional cartilage formation after a week of PGDHi exposure, indicating translational potential for human therapies.

The findings highlight aging pathways as viable targets for tissue rejuvenation and could reduce the need for joint replacements if proven safe and effective in humans.